ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Giant thick melanomas: a retrospective case series.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGiant thick melanomas (GTMs) are rare tumors characterized by extreme size and depth. We aimed to describe their clinical features and outcomes. METHODS/PATIENTS: We retrospectively reviewed eleven patients diagnosed with GTMs at a tertiary dermatology center. GTMs were defined as primary cutaneous melanomas with diameter > 5 cm and Breslow thickness > 4 mm. Tumor size was measured clinically, and all histopathology was reviewed by two dermatopathologists. Clinical, pathological, treatment, and outcome data were extracted from electronic records.
resultsEleven patients (median age 69 years) presented with large tumors (median diameter 55 mm; median Breslow thickness 12 mm), most often on the trunk or extremities. Over half (54.5%) had stage III-IV disease at diagnosis, and treatments included surgery and systemic therapy. Median overall survival was 13 months, with two long-term survivors.
conclusionsGTMs are aggressive and frequently diagnosed at advanced stages. Early recognition and multidisciplinary management are essential. Giant thick melanoma (GTM) is a rare entity characterized by aggressive behavior and poor prognosis. We conducted a retrospective descriptive study defining GTM as lesions with a diameter > 5 cm and Breslow thickness > 4 mm. Eleven cases were analyzed (mean age: 68.5 years), with a female predominance and predominant localization on the trunk. The main reasons for consultation were tumor growth, bleeding, and neurological symptoms. At diagnosis, AJCC stages ranged from IIB to IV. During follow-up, seven patients died -five due to melanoma and two from other causes-, while two remain alive and under active follow-up. Median follow-up was 1 year (range 0-15 years; mean 3.5 years). These findings confirm the severity of GTM and highlight the persistence of diagnostic delay. The main limitation of this study is the small sample size.
Indexed as
Identifiers
41627639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.